Latest Insider Transactions at Poseida Therapeutics, Inc. (PSTX)
This section provides a real-time view of insider transactions for Poseida Therapeutics, Inc. (PSTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Poseida Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Poseida Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
12,389
-3.58%
|
$123,890
$10.0 P/Share
|
|
Feb 10
2021
|
Eric Ostertag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
67,534
+13.53%
|
$67,534
$1.29 P/Share
|
|
Jan 21
2021
|
Eric Ostertag Director |
SELL
Open market or private sale
|
Indirect |
4,462
-1.27%
|
$44,620
$10.0 P/Share
|
|
Jan 15
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,564
+39.71%
|
$7,564
$1.32 P/Share
|
|
Jan 15
2021
|
Johanna Mylet Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,728
+14.99%
|
$0
$0.3 P/Share
|
|
Jan 08
2021
|
Matthew A. Spear Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,921
+50.0%
|
$3,921
$1.32 P/Share
|
|
Jul 14
2020
|
Pharma Ag Novartis > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,908,089
+50.0%
|
-
|